Evidence map›Paper›PMID 36233320›Full record

ArticleInternational journal of molecular sciences2022

Anti-c-MET Fab-Grb2-Gab1 Fusion Protein-Mediated Interference of c-MET Signaling Pathway Induces Methuosis in Tumor Cells.

Xiaoqian Dou, Qinzhi Xu, Bo Dong, Guili Xu, Niliang Qian, Cuima Yang, Hongjie Li, Liting Chen, Xin Gao, Haifeng Song

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaoqian DouState Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China.ORCID 0000-0002-2047-2481
Qinzhi XuBeijng Immunoah Pharma Tech Co., Ltd., Beijing 100071, China.
Bo DongBeijng Immunoah Pharma Tech Co., Ltd., Beijing 100071, China.
Guili XuBeijng Immunoah Pharma Tech Co., Ltd., Beijing 100071, China.
Niliang QianBeijng Immunoah Pharma Tech Co., Ltd., Beijing 100071, China.
Cuima YangBeijng Immunoah Pharma Tech Co., Ltd., Beijing 100071, China.
Hongjie LiBeijng Immunoah Pharma Tech Co., Ltd., Beijing 100071, China.
Liting ChenBeijng Immunoah Pharma Tech Co., Ltd., Beijing 100071, China.
Xin GaoBeijng Immunoah Pharma Tech Co., Ltd., Beijing 100071, China.
Haifeng SongState Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bio-macromolecules have potential applications in cancer treatment due to their high selectivity and efficiency in hitting therapeutic targets. However, poor cell membrane permeability has limited their broad-spectrum application in cancer treatment. The current study developed highly internalizable anti-c-MET antibody Fab fusion proteins with intracellular epitope peptide chimera to achieve the dual intervention from the extracellular to intracellular targets in tumor therapy. In vitro experiments demonstrated that the fusion proteins could interfere with the disease-associated intracellular signaling pathways and inhibit the uncontrolled proliferation of tumor cells. Importantly, investigation of the underlying mechanism revealed that these protein chimeras could induce vacuolation in treated cells, thus interfering with the normal extension and arrangement of microtubules as well as the mitosis, leading to the induction of methuosis-mediated cell death. Furthermore, in vivo tumor models indicated that certain doses of fusion proteins could inhibit the A549 xenograft tumors in NOD SCID mice. This study thus provides new ideas for the intracellular delivery of bio-macromolecules and the dual intervention against tumor cell signaling pathways.

Indexed as

Proto-Oncogene Proteins c-metSignal TransductionAdaptor Proteins, Signal TransducingAnimalsAntibodiesEpitopesGRB2 Adaptor ProteinHumansMiceMice, SCIDPeptidesAdaptor Proteins, Signal TransducingAntibodiesEpitopesGAB1 protein, humanGab1 protein, mouseGRB2 Adaptor ProteinGRB2 protein, humanPeptidesProto-Oncogene Proteins c-metbio-macromoleculesdual interventionFab fusion proteinsintracellular deliverymethuosissignaling pathways

Identifiers

PMID36233320
PMCPMC9569552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.